DXCM$69.54
Chart
Performance
Key Stats
AI DXCM Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyDexCom presents a compelling investment case with strong fundamental growth in the diabetes management sector, supported by positive thematic trends. While technical indicators show some short-term overbought conditions, the overall outlook remains bullish for long-term investors.
Thematic
DexCom is a leader in the rapidly expanding continuous glucose monitoring (CGM) market, driven by increasing diabetes prevalence and technological advancements in health tech.
Fundamental
DexCom demonstrates robust revenue growth, improving profitability, and a solid balance sheet. While the P/E ratio is high, it is justified by the company's market leadership and growth prospects.
Technical
The stock is in a long-term uptrend, trading above key moving averages. However, recent RSI levels suggest potential for a short-term pause or minor pullback.
| Factor | Score |
|---|---|
| Diabetes Technology Adoption | 95 |
| Health Tech Innovation | 90 |
| Aging Population & Chronic Diseases | 80 |
| Digital Health Integration | 85 |
| Regulatory Environment (Medical Devices) | 70 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 75 |
| Growth | 85 |
| Balance Sheet Health | 70 |
| Cash Flow | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 70 |
| Volume Confirmation | 75 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Consistent Earnings Growth
Quarterly EPS estimates have shown positive surprises, with the latest quarter reporting an EPS of $0.50 against an estimate of $0.43, indicating strong profitability and effective management.
Growing Revenue and Market Cap
Revenue has shown a consistent upward trend, reaching $4.03B in 2024, with a corresponding increase in market capitalization to $34.01B, suggesting market confidence in the company's growth prospects.
Bearish Points (8)
High Price-to-Earnings (P/E) Ratio
The trailing P/E ratio of 65.22 is significantly higher than many industry peers, suggesting the stock may be overvalued and sensitive to earnings fluctuations.
Slowing Revenue Growth in Recent Quarters
While annual revenue shows growth, quarterly revenue growth has been fluctuating, with Q1 2025 showing a net margin of 10.2%, indicating potential pressure on profitability compared to previous quarters.
Calendar
July 2025
31
Next Earnings Date
H: $0.49
A: $0.45
L: $0.42
H: 1.15B
A: 1.12B
L: 1.12B
Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Seasonals
Price Target
98.85 USD
The 39 analysts offering 1 year price forecasts for DXCM have a max estimate of 110.00 and a min estimate of 83.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct competitor in the continuous glucose monitoring (CGM) market with its FreeStyle Libre system, which competes directly with Dexcom's G-series devices.
Weight: 95
Major medical device company offering integrated insulin pump and CGM systems (e.g., MiniMed with Guardian Sensor), directly competing in the diabetes management device space.
Weight: 90
Develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems (Eversense), posing a direct competitive threat to Dexcom's less invasive offerings.
Weight: 85
Manufacturer of the Omnipod tubeless insulin pump system, which is often used in conjunction with continuous glucose monitors (including Dexcom's) for automated insulin delivery.